8-K current report · filed Jul 9, 2026

Nurix Therapeutics, Inc. (NRIX) 8-K Current Report: July 9, 2026

Item 2.02Item EX-99.1NRIX overview

Short answer

Nurix Therapeutics, Inc. (NRIX) filed an 8-K current report with the SEC on July 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Nurix announced fiscal-quarter results for the period ended May 31, 2026.

Nurix Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Nurix announced fiscal-quarter results for the period ended May 31, 2026
  • Full financial details and management commentary are contained in Exhibit 99.1, the accompanying press release

Item EX-99.1 · Exhibit EX-99.1

  • Roche collaboration: $700M upfront and up to $2.3B total payments for bexobrutideg, subject to closing conditions
  • Development costs shared 40% Nurix and 60% Roche, with equal U.S. profit/loss sharing and tiered ex-U.S. royalties
  • Bexobrutideg CLL data: 83% ORR and 22.1-month median progression-free survival in Phase 1a
  • Phase 1b ORR reached 92.9% in BTK-treated, BCL2-naïve patients and 84.2% in BTK-naïve patients
  • Cash and securities $443.5M at May 31, 2026, with pro forma cash approximately $1.14B including Roche upfront payment

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Nurix Therapeutics, Inc. 8-K filings

Get the next NRIX 8-K as it lands

Follow NRIX for push alerts, or ask the research agent what this filing means.